Medarex (MEDX) calls active as shares up on prostate cancer treatment report
Medarex (Nasdaq: MEDX) : Medarex is recently up $1.26 to $8.61. The Mayo Clinic online publication Discovery's Edge featured a story about two prostate patients taking MEDX's Ipilumumab and having their PAS drop significantly and the tumors shrinking significantly. MEDX July option implied volatility is at 101, August at 78; verses its six-month average of 93. MEDX call option volume of 5,205 contracts compares to put volume of 460 contracts according to Track Data. Paul Foster
You May Also Be Interested In
- Siliconware Precision (SPIL) Shares Drop on Volatility Spike
- Corinthian Colleges (COCO) Bounces Off Intraday Lows into Close
- Stocks with Implied Volatility Movement; PCX JOY
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
